Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccine

  • Ivan Odak (Geteilte/r Erstautor/in)
  • Lennart Riemann (Geteilte/r Erstautor/in)
  • Inga Sandrock
  • Anne Cossmann
  • Gema Morillas Ramos
  • Swantje I Hammerschmidt
  • Christiane Ritter
  • Michaela Friedrichsen
  • Ahmed Hassan
  • Alexandra Dopfer-Jablonka
  • Metodi V Stankov
  • Leonie M Weskamm
  • Marylyn M Addo
  • Inga Ravens
  • Stefanie Willenzon
  • Anja Schimrock
  • Jasmin Ristenpart
  • Anika Janssen
  • Joana Barros-Martins
  • Gesine Hansen
  • Christine Falk
  • Georg M N Behrens
  • Reinhold Förster

Abstract

BACKGROUND: Human immune responses to COVID-19 vaccines display a large heterogeneity of induced immunity and the underlying immune mechanisms for this remain largely unknown.

METHODS: Using a systems biology approach, we longitudinally profiled a unique cohort of female high and low responders to the BNT162b vaccine, who were known from previous COVID-19 vaccinations to develop maximum and minimum immune responses to the vaccine. We utilized high dimensional flow cytometry, bulk and single cell mRNA sequencing and 48-plex serum cytokine analyses.

FINDINGS: We revealed early, transient immunological and molecular signatures that distinguished high from low responders and correlated with B and T cell responses measured 14 days later. High responders featured a distinct transcriptional activity of interferon-driven genes and genes connected to enhanced antigen presentation. This was accompanied by a robust cytokine response related to Th1 differentiation. Both transcriptome and serum cytokine signatures were confirmed in two independent confirmatory cohorts.

INTERPRETATION: Collectively, our data contribute to a better understanding of the immunogenicity of mRNA-based COVID-19 vaccines, which might lead to the optimization of vaccine designs for individuals with poor vaccine responses.

FUNDING: German Center for Infection Research, German Center for Lung Research, German Research Foundation, Excellence Strategy EXC 2155 "RESIST" and European Regional Development Fund.

Bibliografische Daten

OriginalspracheEnglisch
Aufsatznummer104947
ISSN2352-3964
DOIs
StatusVeröffentlicht - 01.2024

Anmerkungen des Dekanats

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

PubMed 38160529